OPKO Health (OPK) Misses Q3 EPS by 2c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to OPKO Health (OPK) Misses Q3 EPS by 2c, Revenues Beat

OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results

November 5, 2019 4:06 PM EST

MIAMI, Nov. 05, 2019 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2019.

Business Highlights

Somatrogon meets primary and key secondary endpoints in global Phase 3 trial:  On October 21, OPKO and Pfizer announced that the global Phase 3 trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency met its primary endpoint of non-inferiority to GENOTROPIN® (somatropin) injected daily, as measured by annual height velocity at 12 months. ... More